10.07.2012 • News

Linde Raises $1.7 Billion for U.S. Lincare Acquisition

German industrial gases producer Linde raised €1.4 billion ($1.7 billion) from a capital increase to help fund its $4.6 billion purchase of U.S. group Lincare.

The operator of air separation plants for steelmakers and supplier of medical gases said on Tuesday it was issuing 12.84 million new shares at €109 each.

The offer price came in at the bottom of a pricing range of €109.00-111.50 that two traders had provided to Reuters. Linde declined to comment on that range.

Linde said on Monday it would go ahead with a private placement that excluded both subscription rights and a public offer.

As part of Linde's planned acquisition of Lincare, which would make it the world's largest supplier of medical gases, Linde said last week it would increase its capital by up to €1.5 billion.

"The strategic fit is obvious," said Silvia Quandt research analysts Ralf Groenemeyer, reaffirming his buy rating and €130 price target.

"The Lincare acquisition would make the company's earnings less cyclical, actually commanding higher valuation multiples."

Steffen Manske, an analyst with Essen, Germany-based National Bank argued investors had punished the share enough for the sizeable acquisition: "We continue to believe the takeover plan makes sense and is attractive for Linde and regard share price declines of 4% at overdone."

 

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read